Changes in US stocks | Clinical trial results of diet drug Cagrisema fell short of expectations, Novo Nordisk (NVO.US) fell more than 5%

Zhitongcaijing · 03/12 15:49

The Zhitong Finance App learned that Novo Nordisk (NVO.US) fell more than 5% on Wednesday. It has been falling for 4 consecutive days, and is now at $74.16. According to the news, recent test results showed that patients using the highest dose of Cagrisema lost 15.7% of their weight, while those taking placebo lost 3.1% of their weight. Although the company says the results “confirm the excellent efficacy of Cagrisema,” they still fall short of the 25% weight loss target expected by the market. Also, Novo Nordisk's Redefine 1 trial results fell short of expectations.